感染前每日口服抗凝药与新型冠状病毒肺炎住院全因死亡(21天)的关联:一项回顾性队列研究
本研究为回顾性队列研究,纳入某大型高新冠流行医疗系统内≥60岁、新冠病毒聚合酶链反应检测阳性的住院患者,比较入院前及整个病程中使用华法林或直接口服抗凝药者与从未暴露于口服抗凝药者。主要终点为首次开具新冠检测后21天全因住院死亡。直接口服抗凝药组(n=104)21天全因住院死亡率为14.4%,对照组(n=894)为23.8%,未校正OR 0.57(95%CI 0.29-0.92),P=0.03;控制年龄、性别和合并症后OR 0.44(95%CI 0.20-0.90),P=0.033。华法林组(n=28)未校正死亡率为32%,对照组为23.8%,OR 1.51(95%CI 0.64-3.31),P=0.31;校正后观察到死亡率降低但未达统计学显著(OR 0.29,95%CI 0.02-1.62,P=0.24)。各组出血事件数无统计学差异。作者认为这些结果支持未来开展随机对照试验,以了解早期口服抗凝治疗的疗效与风险。
要点
- ≥60岁新冠住院患者中,直接口服抗凝药组(n=104)21天全因住院死亡率为14.4%,对照组(n=894)为23.8%,未校正OR 0.57(95%CI 0.29-0.92),P=0.03。
- 控制年龄、性别和合并症后,直接口服抗凝药组21天全因住院死亡风险仍显著降低(OR 0.44,95%CI 0.20-0.90,P=0.033)。
- 华法林组(n=28)未校正死亡率为32%,对照组为23.8%,OR 1.51(95%CI 0.64-3.31),P=0.31;校正后OR 0.29(95%CI 0.02-1.62),P=0.24,未达统计学显著。
- 各组出血事件数无统计学差异。
- 作者认为这些结果支持未来开展随机对照试验,以了解早期口服抗凝治疗的疗效与风险。
适用人群与场景
- 年龄60岁及以上、因新冠病毒聚合酶链反应检测阳性而住院的患者。
- 研究场景为新冠病毒疾病2019高流行的大型医疗系统。
处置流程与药物剂量
- 比较入院前及整个病程中使用华法林或直接口服抗凝药者与从未暴露于口服抗凝药者。
研究设计与关键结果
- 研究类型为回顾性队列研究(病历回顾),纳入年龄≥60岁、新冠病毒聚合酶链反应检测阳性的住院患者。
- 直接口服抗凝药组n=104,对照组n=894;主要终点为首次开具新冠病毒疾病2019检测后21天全因住院死亡。
- 直接口服抗凝药组21天全因住院死亡率为14.4%,对照组为23.8%,未校正OR 0.57(95%CI 0.29-0.92),P=0.03。
- 控制年龄、性别和合并症后,直接口服抗凝药组OR 0.44(95%CI 0.20-0.90),P=0.033。
- 华法林组n=28,未校正死亡率为32%,对照组为23.8%,OR 1.51(95%CI 0.64-3.31),P=0.31。
- 华法林组校正后观察到死亡率降低但未达统计学显著,OR 0.29(95%CI 0.02-1.62),P=0.24。
- 各组出血事件数无统计学差异。
证据类型、等级与局限
- 证据类型:回顾性队列研究(病历回顾)。
- 作者结论:在感染时及整个病程中每日口服抗凝药的患者21天全因死亡风险显著降低;这些发现应在人群水平上验证;作者认为这些结果支持未来开展随机对照试验,以了解早期口服抗凝治疗的疗效与风险。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为这些结果支持未来开展随机对照试验,以了解早期口服抗凝治疗的疗效与风险;原文未据此给出临床推荐。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVES: Practices regarding anticoagulation use in coronavirus disease 2019 focus primarily on its efficacy in the critically ill without a clear understanding of when to begin anticoagulation. We sought to understand the association of preinfection daily oral anticoagulation use and the short-term mortality of patients hospitalized with coronavirus disease 2019.
DESIGN: Retrospective chart review.
SETTING: Large health system with high coronavirus disease 2019 prevalence.
PATIENTS: Patients 60 years or older admitted to the hospital with positive coronavirus disease 2019 polymerase chain reaction test.
INTERVENTIONS: We compared both those on warfarin and those on a direct oral anticoagulant prior to admission and throughout disease course with those who were never exposed to an oral anticoagulant.
RESULTS: Our primary outcome was inhospital mortality at 21 days from the first coronavirus disease 2019 test ordered. Patients in the direct oral anticoagulant group (n = 104) were found to have significantly lower 21-day all-cause in hospital mortality than patients in the control group (n = 894) both prior to adjustment (14.4% vs 23.8%; odds ratio, 0.57 [0.29-0.92]; p = 0.03) and after controlling for age, gender, and comorbidities (odds ratio, 0.44 [0.20-0.90]; p = 0.033). Patients on warfarin (n = 28) were found to have an elevated unadjusted mortality rate of 32% versus 23.8% in the control group (odds ratio, 1.51 [0.64-3.31]; p = 0.31). After adjustment, a reduction in mortality was observed but not found to be statistically significant (odds ratio, 0.29 [0.02-1.62]; p = 0.24). There was no statistical difference noted in the number of bleeding events in each group.
CONCLUSIONS: In this retrospective cohort study evaluating oral anticoagulant use among patients with coronavirus disease 2019, we found that patients who are on daily oral anticoagulation at the time of infection and throughout their disease course had significantly lower risk of all-cause mortality at 21 days. Validation of these findings should be performed on population-based levels. While research regarding anticoagulation algorithms is ongoing, we believe these results support future randomized control trials to understand the efficacy and risk of the use of early oral anticoagulation.
参考来源
- Harrison RF, Forte K, Buscher MG, et al. The Association of Preinfection Daily Oral Anticoagulation Use and All-Cause in Hospital Mortality From Novel Coronavirus 2019 at 21 Days: A Retrospective Cohort Study. Crit Care Explor. 2021. PMID: 33521644. doi:10.1097/CCE.0000000000000324
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。